Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentury This Week podcast, BioCentury’s Stephen Hansen breaks down the near-term and long-term outlook for a biotech industry hoping to continue the growth of 2H25. BioCentury’s analysts also discuss the impact of the Trump administration’s tariffs on the biopharma industry and last week’s biggest deals: the pending $6.3 billion takeout of Centessa by Eli Lilly and the proposed $5.6 billion acquisition of Apellis by Biogen. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech . Register now as a delegate or apply to join the 2026 Presenting Company Class before the 26th Bio€quity Europe May 4-6 in Prague sells out. View full story: 00:01 - Sponsor Message: IQVIA Biotech 05:09 - 2Q26 Preview 17:09 - Pharma Tariffs 24:04 - C-Path Initiative 26:32 - Lilly Deal 32:19 - Biogen Deal To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 359 - 2Q markets preview, tariffs and biotech takeouts online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts is an episode from BioCentury This Week by BioCentury.

This episode is 38:41 long.

This episode was published on Apr 7, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.